`
` 1
`
`NUVASIVE 1032
`NuVasive, Inc. v. Warsaw Orthopedic, Inc.
`IPR2013-00206
`
`NUVASIVE - EXHIBIT 2002
`Alphatec Holdings Inc. et al. v. NuVasive, Inc.
`IPR2019-00362
`
`
`
`I, Patrick Miles of San Diego, Caiifornia, declare that:
`
`1.
`
`i am currently President of Global Products and Services at NuVasive, Inc., in
`
`San Diego, California.
`
`l have worked at NuVasive since January of 2001. Prior to my
`
`current position, I served as President of the Americas from January 2010 to October 2011,
`
`Executive Vice President of Product Marketing and Development from January 2007 to
`
`December 2009, Senior Vice President of Marketing from December 2004 to January 2007,
`
`and Vice President of Marketing from January 2001 to December 2004.
`
`2.
`
`Prior to starting with NuVasive in 2001, I worked for ORATEC from 1999
`
`through 2001. ORATEC is a medical device company outside the spinal field. Prior to that,
`
`from 1996 through April 1999, i worked at Sofamor Danek (which was acquired by
`
`Medtronic in 1998, becoming Medtronic Sofamor Danek) as Director of Marketing for
`
`Minimally Invasive Systems and Cervical Spine Systems.
`
`3.
`
`Throughout my time at NuVasive, l have been involved at varying levels with
`
`the research, development, and marketing of NuVasive’s XLIF (eXtreme Lateral lnterbody
`
`Fusion) system and procedure.
`
`I started working on the XLIF products and systems in
`
`2001.
`
`l was involved with the launch of the XLIF procedure and products at the North
`
`American Spine Society (‘NASS”) meeting in 2003.
`
`l have been involved in the
`
`commercialization and development of XLIF and its associated products since its launch.
`
`!
`
`am currently listed as an inventor on 51 issued US. patents assigned to NuVasive, many of
`
`which are related to NuVasive‘s XLIF solution.
`
`
`
` 2
`
`
`
`4.
`
`I submit this declaration to correct certain facts and positions stated by
`
`Warsaw Orthopedics in Patent Office proceedings related to the validity of US. Patent No.
`
`8,251,997 to Dr. Gary Michelson (the “”997 patent”), specifically matter numbers IPR2013—
`
`00208 and |PR2013-00208. In connection with providing my rebuttal testimony, I have
`
`reviewed the following documents:
`
`0 U.S. Patent No. 8,251,997 to Michelson (Exhibit 1002).
`
`o
`
`in the inter partes review proceeding lPR2013-00208:
`
`o Warsaw’s Patent Owner Response (especially pages 55—60);
`
`0 Ex. 2038, Declaration of Barton L. Sachs (especially 1111138139);
`
`0
`
`In the inter partes review proceeding |PR2013-00206:
`
`oWarsaw's Patent Owner Response (especially pages 55-60);
`
`0 Ex. 2038, Declaration of Barton L. Sachs (especially 1111138139).
`
`0 Additional exhibits cited below.
`
`5.
`
`My testimony, explained below, is based on my education and experience in
`
`the spinal orthopedics field, including my work experience at Sofamor Danek (and later
`
`Medtronic Sofamor Danek) from 1996 to 1999 and at NuVasive from 2001 to present, my in
`
`depth experience with NuVasive's XLIF solution and the competitive landscape, and my
`
`personal knowledge and involvement in certain events.
`
`6.
`
`On page 57 of the Patent Owner Response, Warsaw states that "[t]he
`
`success of these embodying products is due to the patent features of the ‘997 patent."
`
`2
`
`
`
` 3
`
`
`
`NuVasive's XLIF solution, including its family of CoRoent XL fusion impiants for use in XLlF,
`
`have enjoyed commercial success in the spinal orthopedics market place, and in fact
`
`created the market for lateral fusion products.
`
`It is my opinion that XLIF's success is due to
`
`NuVasive‘s own proprietary innovation and its extensive efforts to commercialize XLIF.
`
`7.
`
`The development of the XLIF solution at NuVastve began in 2001. The XLIF
`
`systems and procedure were initially released at the North American Spine Society Annual
`
`Meeting in late 2003. Our commercialization efforts continued after the 2003 NASS meeting
`into 2004.
`initially, NuVasive’s XLIF solution was met with substantial skepticism within the
`
`spinai orthopedics community. During those early years, we put substantial resources into
`
`training the spinal community to overcome that skepticism and show the spinal community
`
`that the XLIF solution was indeed a safe and effective solution for spinal fusion especially in
`
`the lower lumbar region. We have continued to improve the XLIF solution, specifically
`
`expanding its usability to treat a wider array of spinal issues. Eventually, our success led to
`
`competitors in the marketplace, the first of those being Medtronic Sofamor Danek with its
`
`“DLIF" surgical technique and equipment in the 2006/2007 timeframe. See Medtronic DLIF
`
`Marketing Ptan (Ex. 1053), p. 8 (Medtronic’s own document admitting that "NuVasive
`
`pioneered the approach" and that the approach is “lnnovative"). NuVasive currently has a
`
`patent infringement lawsuit pending in U.S. District Court against lVledtronic, accusing its
`
`DLIF system of infringing NuVasive patents. Additional competitors have also entered the
`
`market with lateral fusion solutions that incorporate many of the important innovations
`
`3
`
`
`
` 4
`
`
`
`developed by NuVaslve. Those other companies include, among others, Globus Medical,
`
`inc. with its Lateral Lumbar lnterbody Fusion (“LLIF") solution introduced in the 2010
`
`timeframe. See id. NuVaslve also has a patent infringement lawsuit pending in U.S. District
`
`Court against Globus Medical because Globus' LLIF soiution also infringes NuVasive
`
`patents.
`
`8.
`
`The success of NuVaslve’s XLlF procedure and system is due, in part, to the
`
`fact that our XLlF solution provides a safe and reproducible minimally disruptive lateral
`
`access path through the psoas muscle (i.e., “trans-psoas”) using tools and techniques that
`
`minimize tissue trauma, reduce blood loss, and allow direct visualization and customization
`
`of the operative corridor during lumbar spinal fusion procedures. XLlF allows a greater
`
`number of spine surgeons with varying skills and experience to perform a lateral approach
`
`to the lumbar spine through the highly innervated psoas muscle. Prior to XLlF, the lateral
`
`approach, which dates back to at least the 1980s, was limited to a handful of highly skilled
`
`surgeons performing techniques that were quickly abandoned because they provided mixed
`
`results. Those prior lateral techniques failed to achieve any level of success in the
`
`marketplace.
`
`9.
`
`Some key factors to XLlF’s success include: (A) a surgical finger-sweep and
`
`finger guidance technique to help create a safe passage through the retroperitoneal space
`and deliver surgical instruments safely to the spine (see, e.g., US. Patent No. T,905,840,
`
`Exhibit 1059); (B) a minimally disruptive access system with integrated nerve monitoring
`
`4
`
`
`
` 5
`
`
`
`capabilities designed to gradually dilate a path to the spine through the highly innervated
`
`psoas muscle (see, e.g., US. Patent No. 8,000,535, 8,000,782 and D652,922, Exhibits
`
`1061, 1062, 1064); (C) a bladed retractor system to aid in the direct visualization of the
`
`spinal surgical site with the ability to customize the operative corridor (see, e.g., US. Patent
`
`No. 8,192,356 and 8,016,767, Exhibits 1063 and 1070); and (D) a patented fusion implant
`
`design that, unlike the implants disclosed in the ‘997 patent, does not require the removal of
`
`portions of the adjacent vertebrae (see, e.g., US. Patent Nos. 8,187,334 and 8,361,156,
`
`Exhibits 1065 and 1066). Based on my review, the ‘997 patent does not claim or even
`
`mention any of these features.
`
`10.
`
`NuVasive expended substantial capital and human resources in developing
`
`its innovations and in the commercialization of XLIF.
`
`I estimate that about $20-30lVl was
`
`expended by NuVasive on the initial development of NuVasive's XLIF solution from the
`
`middle of 2001 to the Fall of 2004. Since that time, NuVasive has continued its
`
`development work related to the XLIF solution and has continued to expend considerable
`
`resources in connection with that.
`
`11.
`
`NuVasive’s pioneering XLIF systems and procedure have enjoyed wide
`
`acceptance from the spine surgeon community and praise from those in that community.
`
`See Thompson Weisel Partners, Bending the Paradigm (Ex. 1051), p. 12 (crediting
`
`NuVasive with "Pioneering" the MIS fusion market, noting that “Surgeon feedback is
`
`overwhelmingly positive," and concluding that NuVasive’s technology is “much more
`
`5
`
`
`
` 6
`
`
`
`physician friendly and useful than previous offerings from larger competitors, such as
`
`Medtronic); A New Solution (Ex. 2051), p. 1 (crediting NuVasive with the development of the
`
`procedure); Ehrhardt, Birmingham Medical News (Ex. 1052) (noting that a lateral procedure
`
`was difficult to reproduce in the 1990’s until the “breakthrough" XLiF equipment in 2004);
`
`Thomas Weisel Partners - Bending the Paradigm (Ex. 1051), p. 58 (explaining that the
`
`extreme lateral approach was “largely avoided in the past” before XLIF made the path
`
`vlabie); Medtronic DLIF Marketing Plan (Ex. 1053), p. 8 (Medtronic’s own document
`
`admitting that “NuVaslve pioneered the approach" and that the approach is “lnnovative");
`
`Rodgers, Experience and Early Results with a Minimally Invasive Technique for Anterior
`
`Column Support Through eXtreme Lateral Interbody Fusion (Ex. 1054), p. 28, 32 (stating
`
`“XLIF technology is revolutionizing the care of patients" and that “it is impossible to
`
`overemphasize the importance of reliable, timely monitoring of the neural elements as the
`
`surgeon traverses the psoas.").
`
`12.
`
`NuVasive's implants designed for use in lateral procedures, called the
`
`CoRoent XL family of implants, have generally flat upper and lovver surfaces designed to
`
`bear against the adjacent vertebrae without requiring bony portions of the adjacent
`
`vertebrae to be cut/drilied and removed.
`
`In this manner, NuVasive’s CoRoent impiants are
`
`significantly unlike the implants illustrated in Dr. Michelson’s ‘997 patent based on my
`
`review. For example, a drawing of one version of the CoRoent XL implants from
`
`NuVasive’s US. Patent No. 8,187,334 (Exhibit 1065) (left) is compared with a drawing from
`
`6
`
`
`
` 7
`
`
`
`Dr. Michelson’s preferred cylindrical lumbar cage implant of the ‘997 patent (Exhibit 1002,
`
`dghd.
`
`
`
`
`
`NuVasive CoRoent lm lant Michelson ‘997 Implants
`
`13.
`
`I am also aware that other spine medical device companies have launched
`
`lateral access solutions in an effort to compete with NuVasive’s XLIF. Based on my
`
`knowledge of those competitive systems, all of them include at least the nerve monitoring
`
`capability that NuVasive pioneered to traverse the innervated psoas muscle, as well as
`
`stimulated sequential dilation, split—blade retractors, and implants designed for lateral
`
`insertion. See Dr. Sachs Decl. at 11 138 (listing lateral fusion solutions from Globus Medical,
`
`Synthes, DuPuy and Stryker).
`
`14.
`
`l have reviewed pages 59-60 of Warsaw’s Patent Owner Response, and I
`
`disagree with the statement there that Mr. Valentine, Mr. Lukianov, and l engaged in
`
`7
`
`
`
` 8
`
`
`
`“copying of claimed technology by a competitor." We did no such thing. The XLiF-related
`
`equipment and procedures conceived and developed at NuVasive during the 2001-2004
`
`timeframe are substantially different from anything we were involved with or had access to
`
`at Sofamor Danek in the 19903. I had no personal knowledge of Dr. Michelson’s lateral
`
`solution or any patent filings on that, when l was working at Sofamor Danek. Moreover, I
`
`am aware from my involvement in the litigation between Medtronic and NuVasive, that
`
`neither Dr. Michelson nor iVlr. Lukionov remember a meeting where Mr. Lukionov saw Dr.
`
`Michelson’s lateral solution. Nuvasive’s XLIF solution was the result of the significant effort
`
`and resources NuVasive invested into developing a lateral solution that was contrary to the
`
`accepted wisdom at the time between 2001-2004, as discussed above. Finally, I understand
`
`that the ‘997 patent was not even issued as a patent until 2012, almost a decade after we
`
`released our XLIF solution to the market.
`
`15.
`
`In addition, Warsaw's reference on page 60 of its Patent Owner Response to
`
`Sofamor Danek’s “ELIF" project for which I was responsible is misleading. The “ELIF”
`
`project at Sofamor Danek fell under my oversight responsibility. As such, I have personal
`
`knowledge that ELiF was an endoscopic procedure.
`
`Indeed ELIF was an acronym for
`
`“Endoscopic Lumbar lnterbody Fusion" during the entire time that l was involved with the
`
`project at Sofamor Danek. I never heard ELIF referred to as "Extreme Lateral lnterbody
`
`Fusion” during that time.
`
`It was only in connection with NuVasive’s legal disputes with
`
`Medtronic (which started in 2008) that | first heard the contention that ELIF supposedly
`
`8
`
`
`
` 9
`
`
`
`referred to "Extreme Lateral Interbody Fusion." That is simply not true. ELlF was a failed
`
`project, in part, because the data showed that the access corridor was not predictable and
`
`there was a danger of potentially tearing the vena cava blood vesset (one of the body‘s
`
`great vessels).
`
`16.
`
`I personally came up with the name "eXtreme Lateral interbody Fusion" and
`
`the "XLIF" acronym for that name after E came to NuVasive, and came up with that name
`
`and acronym with no knowledge of ELtF ever having been an acronym for “Extreme Lateral
`
`lnterbody Fusion."
`
`17.
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that atl statements made on information and belief are believed to be true; and
`
`further that these statements were made with the knowledge that willful false statements
`
`and the like so made are punishable by tine or imprisonment, or both, under Sectton 1001 of
`
`the Title 18 of the United States Code and that such willful false statements may jeopardize
`
`the validity of the application or any patents issued thereon.
`
`Dated: March 10, 2014
`
`W8
`
`31ka
`
`Patrick Miles
`
`10
`
`
`
`10
`
`